Evidence map›Paper›PMID 28856009›Full record

ArticleCanadian journal of kidney health and disease2017

The Chronic Kidney Disease Water Intake Trial: Protocol of a Randomized Controlled Trial.

William F Clark, Shih-Han Huang, Amit X Garg, Kerri Gallo, Andrew A House, Louise Moist, Matthew A Weir, Jessica M Sontrop

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of kidney health and disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01766687 (A Randomized Controlled Trial of Increased Water Intake in Chronic Kidney Disease), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01766687 nacompletednot on this map

A Randomized Controlled Trial of Increased Water Intake in Chronic Kidney Disease

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2013 to 2017Enrolled822ConditionsChronic Kidney DiseaseArmsHydration
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Chronic kidney disease in Indonesia: evidence from a national health survey.Osong public health and research perspectives · 2023
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

William F ClarkVictoria Hospital, London, Ontario, Canada.
Shih-Han HuangVictoria Hospital, London, Ontario, Canada.
Amit X GargVictoria Hospital, London, Ontario, Canada.
Kerri GalloVictoria Hospital, London, Ontario, Canada.
Andrew A HouseUniversity Hospital, London, Ontario, Canada.
Louise MoistVictoria Hospital, London, Ontario, Canada.
Matthew A WeirUniversity Hospital, London, Ontario, Canada.
Jessica M SontropVictoria Hospital, London, Ontario, Canada.
Victoria Hospital · CAUniversity Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn observational studies, drinking more water associates with a slower rate of kidney function decline; whether the same is true in a randomized controlled trial is unknown.

objectiveTo examine the 1-year effect of a higher vs usual water intake on estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease.

designParallel-group randomized controlled trial.

settingNine centers in Ontario, Canada. Enrollment and randomization occurred between May 2013 and May 2016; follow-up for the primary outcome will continue until June 2017.

participantsAdults (n = 631) with stage 3 chronic kidney disease (eGFR 30-60 mL/min/1.73 m

interventionThe high water intake group was coached to increase their oral water intake by 1.0 to 1.5 L/day (depending on sex and weight), over and above usual consumed beverages, for a period of 1 year. The control group was coached to maintain their usual water intake during this time. MEASURES: Participants provided 24-hour urine samples at baseline and at 6 and 12 months after randomization; urine samples were analyzed for volume, creatinine, osmolality, and the albumin-to-creatinine ratio. Blood samples were obtained at baseline and at 3- to 6-month intervals after randomization, and analyzed for creatinine, copeptin, osmolality, and electrolytes. Other measures collected included health-related quality of life, blood pressure, body mass index, and diet. PRIMARY OUTCOME: The between-group change in eGFR from baseline (prerandomization) to 12 months after randomization. SECONDARY OUTCOMES: Change in plasma copeptin concentration, 24-hour urine albumin-to-creatinine ratio, measured creatinine clearance, estimated 5-year risk of kidney failure (using the 4-variable Kidney Failure Risk Equation), and health-related quality of life. PLANNED ANALYSIS: The primary analysis will follow an intention-to-treat approach. The between-group change in eGFR will be compared using linear regression. Supplementary analyses will examine alternative definitions of eGFR change, including annual percentage change, rate of decline, and rapid decline (a

trial registrationThis randomized controlled trial has been registered at www.clinicaltrials.gov; government identifier: NCT01766687.

Indexed as

chronic kidney diseasecopeptinestimated glomerular filtration raterandomized controlled trialvasopressinwater intake

Identifiers

PMID28856009
PMCPMC5571765
OpenAlexW2748273376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.